Chang C C, Naiki M, Halpern G M, Gershwin M E
Department of Internal Medicine, School of Medicine, University of California at Davis 95616.
J Investig Allergol Clin Immunol. 1993 Jan-Feb;3(1):8-18.
Immunomodulators include any agent or substance that has an effect on the host immune system. These effects may be stimulatory, suppressive or regulatory. Many drugs, chemicals and microbial products have been identified as having specific as well as nonimmunostimulating properties. The first agent to be used clinically as an immunostimulating drug was Bacillus Calmette-Guerin (BCG). Subsequently, other bacterial derivatives, including Corynebacterium parvum and bacterial lipopolysaccharides, were found to have stimulatory effects. Most research in immunostimulating agents has been done in cancer chemotherapy, where such compounds or preparations have been employed to (hopefully) restore chemotherapeutic agent-induced immunosuppression, and thus prevent the development of community-acquired or nosocomial infections. In contrast to immunostimulants, immunoregulators are traditionally defined as being capable of decreasing an abnormally elevated immune response, and therefore restore defective immune function. However, the differentiation between immunoregulators and immunostimulants is not always clearly defined, as the regulatory effects on the immune system of any particular drug may be multifaceted. Clearly, future research must be directed at defining the specific mechanisms of action of potential therapeutic drugs, and in developing improved molecules to ensure safety and efficacy in the clinical setting.
免疫调节剂包括任何对宿主免疫系统有影响的制剂或物质。这些影响可能是刺激性的、抑制性的或调节性的。许多药物、化学物质和微生物产物已被确定具有特定以及非免疫刺激特性。临床上首个用作免疫刺激药物的制剂是卡介苗(BCG)。随后,发现其他细菌衍生物,包括短小棒状杆菌和细菌脂多糖,具有刺激作用。免疫刺激剂的大多数研究是在癌症化疗中进行的,在该领域此类化合物或制剂已被用于(有望)恢复化疗药物引起的免疫抑制,从而预防社区获得性感染或医院感染的发生。与免疫刺激剂相反,免疫调节剂传统上被定义为能够降低异常升高的免疫反应,从而恢复有缺陷的免疫功能。然而,免疫调节剂和免疫刺激剂之间的区分并不总是明确的,因为任何特定药物对免疫系统的调节作用可能是多方面的。显然,未来的研究必须致力于确定潜在治疗药物的具体作用机制,并开发改良的分子以确保在临床环境中的安全性和有效性。